Cipher Pharmaceuticals Inc. (T:CPH)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Apr 03, 2024 07:05 am ET

Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Mississauga, Ontario--(Newsfile Corp. - April 3, 2024) - Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Mar 14, 2024 05:00 pm ET

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results

(All figures are presented in U.S. Dollars)

Mar 08, 2024 06:00 am ET

Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call

MISSISSAUGA, ON, March 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and full year of 2023 after the market close on Thursday, March 14, 2024. The Company will also hold a conference call on Friday, March 15 at 8:30 ET to discuss the results and corporate developments.

Jan 29, 2024 07:00 am ET

OTC Markets Group Welcomes Cipher Pharmaceuticals Inc. to OTCQX

OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cipher Pharmaceuticals Inc. (TSX: CPH; OTCQX: CPHRF), a specialty pharmaceutical company, has qualified to...

Jan 29, 2024 06:15 am ET

Cipher Pharmaceuticals Announces the Commencement of OTCQX Trading

MISSISSAUGA, ON, Jan. 29, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or "the Company") is proud to announce that its common shares are now trading on the OTCQX® Best Market ("OTCQX") under the symbol "CPHRF." The OTCQX is the highest market tier of OTC Markets on which 12,000 U.S. and global securities trade. Trading on OTCQX will enhance the visibility and accessibility of the Company to U.S. investors. Cipher's common shares will continue to trade on the Toronto Stock Exchange ("TSX") under the symbol "CPH".

Nov 24, 2023 04:00 pm ET

Cipher Pharmaceuticals Announces Change of Auditor

MISSISSAUGA, ON, Nov. 24, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it has changed its auditors from Ernst & Young LLP ("Former Auditor") to RSM Canada LLP ("Successor Auditor") effective November 23, 2023. At the request of the Company, the Former Auditor resigned as the auditor of the Company effective November 23, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective November 23, 2023, until the next Annual General Meeting of the Company.

Nov 15, 2023 04:00 pm ET

Cipher Pharmaceuticals Announces Normal Course Issuer Bid

MISSISSAUGA, ON, Nov. 15, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").

Nov 09, 2023 04:00 pm ET

Cipher Pharmaceuticals Reports Strong Sales & Earnings Growth in Q3 2023

(All figures are presented in U.S. dollars)

Oct 27, 2023 07:00 am ET

Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call

MISSISSAUGA, ON, Oct. 27, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the third quarter of 2023 on Thursday, November 9, 2023. The Company will also host a conference call on Friday, November 10, 2023 at 8:30am ET to discuss the results and corporate developments.

Oct 12, 2023 09:57 am ET

Cipher Pharmaceuticals Announces Final Results of Substantial Issuer Bid

MISSISSAUGA, ON, Oct. 12, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company"), today announced the final results of its substantial issuer bid (the "Offer"), which expired at 5:00 p.m. (Eastern Time) on October 11, 2023.

Oct 03, 2023 07:00 am ET

Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid

MISSISSAUGA, ON, Oct. 3, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company"), today provided a reminder of its previously announced substantial issuer bid (the "Offer" or "SIB") under which the Company has offered to purchase for cancellation up to $6,000,000 of its outstanding common shares (the "Common Shares").

Sep 05, 2023 07:00 am ET

Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars

MISSISSAUGA, ON, Sept. 5, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company"), is announcing its intention to commence a substantial issuer bid (the "Offer" or "SIB") pursuant to which the Company will offer to purchase for cancellation up to $6,000,000 of its outstanding common shares (the "Common Shares"). The Offer commences on September 6, 2023 and will expire on October 11, 2023, unless extended, varied or withdrawn.

Aug 10, 2023 05:00 pm ET

Cipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in Mexico

(All figures are presented in U.S. dollars)

Jul 28, 2023 07:00 am ET

Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call

MISSISSAUGA, ON, July 28, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the second quarter of 2023 on Thursday, August 10, 2023. The Company will also host a conference call on Friday, August 11, 2023 at 8:30am ET to discuss the results and corporate developments.

Jul 05, 2023 07:00 am ET

Cipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European Union

Significant regulatory milestone reached by Moberg, paving the way for their commercial launch across 13 countries in EuropeCipher holds exclusive Canadian rights to MOB-015 and sees the approval in the European Union as an important step forward towards approval in North AmericaMISSISSAUGA, ON, July 5, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological

Jun 21, 2023 12:53 pm ET

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders

MISSISSAUGA, ON, June 21, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 10, 2023 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of Ernst & Young LLP as auditor of the Company and approving the change o

May 11, 2023 05:00 pm ET

Cipher Pharmaceuticals Reports First Quarter Results, Highlighted by Record Cash Per Share and Strong Financial Flexibility

(All figures are presented in U.S. dollars)

May 04, 2023 05:00 pm ET

Cipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference Call

MISSISSAUGA, ON, May 4, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the first quarter of 2023 on Thursday, May 11, 2023. The Company will also host a conference call on Friday, May 12, 2023 at 8:30am ET to discuss the results and corporate developments.

Apr 18, 2023 05:00 pm ET

Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Mississauga, Ontario--(Newsfile Corp. - April 18, 2023) - Cipher Pharmaceuticals (TSX: CPH), a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.

Mar 16, 2023 05:00 pm ET

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

(All figures are in U.S. dollars)

Mar 10, 2023 04:30 pm ET

Cipher Pharmaceuticals Schedules Q4 2022 Earnings Release and Conference Call

MISSISSAUGA, ON, March 10, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the three and twelve months ended December 31, 2022 after market close on March 16, 2023. The Company will also host a conference call on Friday, March 17, 2023 at 8:30am ET to discuss the results and corporate developments.

Mar 01, 2023 06:00 am ET

Cipher Pharmaceuticals Announces Closing of New US$35 Million Credit Facility

MISSISSAUGA, ON, March 1, 2023 /CNW/ - Feb 28, 2023 - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced completion and closing of a new credit facility (the "Credit Facility") with Royal Bank of Canada (RBC).

Nov 10, 2022 05:30 pm ET

Cipher Pharmaceuticals Reports Strong Third Quarter Results, Highlighted by USD$1.09 in Cash Per Share

(All figures are presented in U.S. dollars)

Oct 26, 2022 07:00 am ET

CIPHER PHARMACEUTICALS SCHEDULES Q3 2022 EARNINGS RELEASE AND CONFERENCE CALL

OAKVILLE, ON, Oct. 26, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2022 financial results on Thursday, November 10, 2022 after market close. The company will hold a conference call on Friday, November 11, 2022 at 8:30am ET to discuss the results and corporate developments.

Sep 19, 2022 05:00 pm ET

Cipher Pharmaceuticals Announces Normal Course Issuer Bid

MISSISSAUGA, ON, Sept. 19, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").

Aug 11, 2022 05:45 pm ET

Cipher Pharmaceuticals Strengthens Leadership Team with Appointment of New CFO

Experienced finance executive Bryan Jacobs, CPA, CA to join the Company as CFO, effective August 15, 2022.

Aug 11, 2022 05:01 pm ET

Cipher Pharmaceuticals Reports Second Quarter 2022 Financial Results

(All figures are in U.S. dollars)

Aug 05, 2022 07:00 am ET

Cipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference Call

MISSISSAUGA, ON, Aug. 5, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q2 2022 financial results on Thursday, August 11, 2022 after market close. The Company will also host a conference call on Friday, August 12, 2022 at 8:30am ET to discuss the results and corporate developments.

Jul 21, 2022 05:18 pm ET

Choice Properties Real Estate Investment Trust Reports Results for the Six Months Ended June 30, 2022

Choice Properties Real Estate Investment Trust (“Choice Properties” or the “Trust”) (TSX: CHP.UN) today announced its consolidated financial results for the three and six months ended June 30, 2022. The 2022 Second Quarter Report to Unitholders is available in the Investors section of the Trust’s website at www.choicereit.ca, and has been filed on SED

Jun 22, 2022 05:01 pm ET

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John Mull

MISSISSAUGA, ON, June 22, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 13, 2022 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of Ernst & Young LLP as the Company's auditors and approving the unalloca

May 12, 2022 05:00 pm ET

Cipher Pharmaceuticals Reports Strong First Quarter 2022 Financial Results

(All figures are in U.S. dollars)

May 09, 2022 07:00 am ET

Cipher Pharmaceuticals Schedules Q1 2022 Earnings Release and Conference Call

OAKVILLE, ON, May 9, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q1 2022 financial results on Thursday, May 12, 2022 after market close. The Company will also host a conference call on Friday, May 13, 2022 at 8:30am ET to discuss the results and corporate developments.

Mar 22, 2022 05:00 pm ET

Cipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 Study

MISSISSAUGA, ON, March 22, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has submitted a regulatory filing for the next clinical Phase 3 study for MOB-015 (nail fungus treatment) to the U.S. Food and Drug Administration ("FDA").

Mar 17, 2022 05:00 pm ET

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Demonstrated growth in FY 2021 as EBITDA increased 46% to $11.8 million Disciplined cost structure led to an 18% reduction in SG&A 81% increase in EPS to $0.29 in FY2021 Strengthened cash flow from operations; Cash at December 31, 2021 was $20.5 million Subsequent to year-end, bolstered isotretinoin portfolio through extended distribution and supply agreement with Sun Pharmaceutical to December 31, 2026 MISSISSAUGA, ON, March 17, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the year ended December

Mar 11, 2022 04:00 pm ET

Cipher Pharmaceuticals Schedules Q4 2021 Earnings Release and Conference Call

MISSISSAUGA, ON, March 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021 after market close on March 17, 2022. The Company will also host a conference call on Friday, March 18, 2022 at 8:30am ET to discuss the results and corporate developments.

Mar 10, 2022 06:00 am ET

Cipher Pharmaceuticals Announces Extension of Distribution and Supply Agreement with Sun Pharmaceutical Industries Inc.

Royalty agreement granting Sun Pharmaceutical Industries Inc. exclusive right to market, sell and distribute Absorica, Absorica AG and Absorica LD in the U.S. extended through December 31, 2026

Nov 11, 2021 04:01 pm ET

Cipher Announces Third Quarter and Year-to-Date 2021 Financial Results

Revenue for nine months ended September 30, 2021increases 4.1% to $16.1 million Adjusted EBITDA1 for nine months ended September 30, 2021 increases to $9.8 million Basic EPS for the nine months ended September 30, 2021 increases 12% to $0.19 (CDN$0.242) Excluding one-time charges, EPS for the nine months ended September 30, 2021 was $0.263 (CDN$0.33) The Canadian product revenue increased 30% during the nine months ended September 30, 2021 compared to the similar period in 2020. During the quarter, the Company assigned the office lease for its corporate head office which will result in a sav

Nov 03, 2021 05:01 pm ET

Cipher Pharmaceuticals Schedules Q3 2021 Earnings Release and Conference Call

OAKVILLE, ON, Nov. 3, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2021 financial results on Thursday, November 11, 2021. The company will hold a conference call on Friday, November 12, 2021 at 8:30am ET to discuss the results.

Sep 08, 2021 07:30 am ET

Cipher Pharmaceuticals Announces Renewal of Normal Course Issuer Bid

OAKVILLE, ON, Sept. 8, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to renew its normal course issuer bid ("NCIB") for its common shares (the "Common Shares").

Aug 12, 2021 05:00 pm ET

Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica

Revenue increases 30% to $6.1 million, Adjusted EBITDA2 increases 40% to $4.1 million EPS increases 450% to $0.11 (CDN$0.141) Epuris revenue grows 63%, Absorica revenue grows 25% All figures in U.S. dollars, unless otherwise noted OAKVILLE, ON, Aug. 12, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six-months ended June 30, 2021. Unless otherwise noted, all figures are in U.S. dollars.

Aug 09, 2021 07:30 am ET

Cipher Pharmaceuticals Schedules Q2 2021 Earnings Release and Conference Call

OAKVILLE, ON, Aug. 9, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2021 financial results on Thursday, August 12, 2021. The company will hold a conference call on Friday, August 13, 2021 to discuss the results.

Jun 23, 2021 05:30 pm ET

Cipher Pharmaceuticals Reports Voting Results From Annual Meeting of Shareholders

OAKVILLE, ON, June 23, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today.

May 13, 2021 05:00 pm ET

Cipher Pharmaceuticals Reports First Quarter 2021 Financial Results

Generates Adjusted EBITDA of $3.6 million and EPS of $0.05 (CDN$0.61) Excluding legal provision EPS was $0.10 (CDN$0.12) OAKVILLE, ON, May 13, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31, 2021. Unless otherwise noted, all figures are in U.S. dollars.

May 05, 2021 05:00 pm ET

Cipher Pharmaceuticals Schedules Q1 2021 Earnings Release and Conference Call

OAKVILLE, ON, May 5, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. The company will hold a conference call on Friday, May 14, 2021 to discuss the results.

Mar 25, 2021 07:00 am ET

Cipher Pharmaceuticals Announces Automatic Repurchase Plan Pursuant to its Normal Course Issuer Bid

OAKVILLE, ON, March 25, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has received approval from the Toronto Stock Exchange ("TSX") to amend its normal course issuer bid ("NCIB") in order to enter into an automatic repurchase plan with its designated broker. The automatic repurchase plan enables Cipher to provide standard instructions in the future and then purchase common shares on the open market during self-imposed blackout periods.

Mar 18, 2021 05:00 pm ET

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 10, 2021 05:26 pm ET

Cipher Pharmaceuticals Schedules Q4 2020 Earnings Release and Conference Call

OAKVILLE, ON, March 10, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021. The company will hold a conference call on Friday, March 19, 2021 to discuss the results.

Feb 10, 2021 04:30 pm ET

Cipher Pharmaceuticals Enters into Co-Promotion Agreement with Verity Pharmaceuticals Inc.

OAKVILLE, ON, Feb. 10, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has entered into an exclusive co-promotion agreement (the "Agreement") with Verity Pharmaceuticals Inc. for the marketing, sales and co-promotion of Brinavess, Aggrastat and Trevyent.

Jan 15, 2021 05:00 pm ET

Cipher Pharmaceuticals Receives Arbitration Award on Trulance®

OAKVILLE, ON, Jan. 15, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health Ireland ("Bausch Health") relating to the License, Development and Commercialization Agreement (the "Agreement") of Trulance®. As previously disclosed, the Company received a notice of termination from Bausch Health for alleged breach of contract in respect of its licensing agreement for Trulance®.

Nov 12, 2020 06:30 pm ET

Cipher Pharmaceuticals Reports Third Quarter 2020 Financial Results

Revenue Increases Sequentially to $4.9 millionEBITDA2 was $2.7 million or 55% of net revenue

Nov 03, 2020 04:00 pm ET

Cipher Pharmaceuticals Schedules Q3 2020 Earnings Release and Conference Call

OAKVILLE, ON, Nov. 3, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q3 2020 financial results after the close on Thursday, November 12, 2020. The Company will hold a conference call on Friday, November 13, 2020 to discuss the results.

Oct 08, 2020 08:24 pm ET

Cipher Pharmaceuticals Reports Voting Results for the Election of Directors

Announces Appointment Of Cathy Steiner To Board Of Directors

Aug 12, 2020 06:20 pm ET

Cipher Pharmaceuticals Announces Normal Course Issuer Bid

OAKVILLE, ON, Aug. 12, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, a Notice of Intention to Make a Normal Course Issuer Bid (the "Notice").

Aug 12, 2020 05:00 pm ET

Cipher Pharmaceuticals Reports Second Quarter 2020 Financial Results

Income before taxes increased 36% to $2.5 millionEBITDA increased 22% to $2.9 millionExcluding a one-time tax adjustment EPS was $0.07 (CDN$0.10)

Jul 27, 2020 05:00 pm ET

Cipher Pharmaceuticals Schedules Q2 2020 Earnings Release and Conference Call

OAKVILLE, ON, July 27, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2020 financial results after the close on Wednesday, August 12, 2020. The Company will hold a conference call on Thursday, August 13, 2020 to discuss the results.

Jul 02, 2020 06:00 pm ET

Cipher Pharmaceuticals Appoints New Chief Financial Officer

OAKVILLE, ON, July 2, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer (CFO), he will succeed Interim CFO Nadine Jutlah.

May 07, 2020 08:00 pm ET

Cipher Pharmaceuticals Reports First Quarter 2020 Financial Results

Earnings per common share increases to $0.10 ($0.13 in Canadian Dollars1)

Apr 27, 2020 09:56 pm ET

Cipher Pharmaceuticals Schedules Q1 2020 Earnings Release and Conference Call

OAKVILLE, ON, April 27, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2020 financial results on Thursday, May 7, 2020. The company will hold a conference call on Friday, May 8, 2020 to discuss the results.

Apr 20, 2020 07:57 pm ET

Cipher Pharmaceuticals Receives Positive Ruling on Binding Arbitration with Upsher-Smith Laboratories

OAKVILLE, ON, April 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the Company has been successful in its binding arbitration with Upsher-Smith Laboratories LLC ("Upsher-Smith").

Mar 25, 2020 06:00 pm ET

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter

Feb 20, 2020 04:00 pm ET

Notice of Cipher Pharmaceuticals Q4 2019 Conference Call

OAKVILLE, ON, Feb. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2020 financial results conference call on Thursday, March 26, 2019.

Feb 06, 2020 04:30 pm ET

Cipher Pharmaceuticals Provides Update on Absorica Brand Extension Program with Sun Pharmaceutical

OAKVILLE, ON, Feb. 6, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") is pleased to announce that Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), the Company's U.S. marketing partner for Absorica®, has launched ABSORICA LD™ (isotretinoin) capsules in the U.S for the management of severe recalcitrant nodular acne in patients 12 years of age and older.

Jan 20, 2020 05:00 pm ET

Cipher Pharmaceuticals Receives Notice of Termination from Bausch

OAKVILLE, ON, Jan. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the Company received a Notice of Termination (the "Notice") from Bausch Health in connection with the License, Development and Commercialization Agreement (the "Agreement") of Trulance® (plecanatide). The Notice alleges that Cipher is in breach of certain unspecified provisions of the Agreement.

Nov 07, 2019 06:00 am ET

Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results

Revenue increased 20% to $5.8 million

Oct 24, 2019 05:00 pm ET

Notice of Cipher Pharmaceuticals Q3 2019 Conference Call

OAKVILLE, ON, Oct. 24, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2019 financial results conference call on Thursday, November 7, 2019.

Oct 18, 2019 07:00 am ET

Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)

OAKVILLE, ON, Oct. 18, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received Health Canada approval, on October 10, 2019, for TRULANCE® (plecanatide), a Guanylate cyclase-C (GCC) agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation ("IBS-C").

Aug 09, 2019 07:00 am ET

Cipher Pharmaceuticals Reports Second Quarter 2019 Financial Results

Company also provides update on strategic priorities

Jul 30, 2019 07:30 am ET

Notice of Cipher Pharmaceuticals Q2 2019 Conference Call

OAKVILLE, ON, July 30, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2019 financial results conference call on Friday, August 9, 2019.

Jul 29, 2019 09:00 am ET

Cipher Pharmaceuticals Announces Management Change & Preliminary Q2 Financial Highlights

Company also forms Special Committee

Jun 12, 2019 08:30 am ET

Cipher Pharmaceuticals Reports Voting Results for the Election of Directors

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its Annual and Special Meeting of Shareholders held...

May 10, 2019 07:00 am ET

Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

Revenue increased by 12% to $5.1 million

May 01, 2019 07:30 am ET

Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

OAKVILLE, ON, May 1, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10, 2019. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Nadine Jutlah, Interim Chief Financial Officer. The Company will issue its financial results on the morning of May 10, 2019.

Mar 26, 2019 07:00 am ET

Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

OAKVILLE, ON, March 26, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately.

Mar 20, 2019 07:00 am ET

Cipher Pharmaceuticals Announces Change to Management Team

OAKVILLE, ON, March 20, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has resigned to pursue other career opportunities. Mr. Lemieux will leave the Company on March 29, 2019. Mr. Lemieux has agreed to a consulting agreement with the Company to assist in the orderly transition of his responsibilities.

Mar 19, 2019 07:00 am ET

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Canadian product revenue increased 30% to $6.9 million for the year Completed six (6) strategic business transactions enhancing long-term value

Mar 15, 2019 05:05 pm ET

Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

OAKVILLE, ON, March 15, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2018 financial results conference call on Tuesday, March 19, 2019. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer. The Company will issue its financial results on the morning of March 19, 2019.

Dec 18, 2018 06:00 am ET

Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

MISSISSAUGA, ON, Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada. Cipher acquired the exclusive Canadian rights to distribute and commercialize A-101 40% from Aclaris Therapeutics, Inc. (NASDAQ:ACRS) ("Aclaris") in April 2018.

Dec 17, 2018 06:00 am ET

Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

MISSISSAUGA, ON, Dec. 17, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) ("Synergy") in February 2018. TRULANCE® is a once-daily tablet approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adults with IBS-C.

Dec 05, 2018 10:00 am ET

Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

MISSISSAUGA, ON, Dec. 5, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET.

Dec 04, 2018 06:00 am ET

Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations

MISSISSAUGA, ON, Dec. 4, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice President, Canadian Commercial Operations. Mr. Milloy has more than 20 years of pharmaceutical industry experience in the commercialization of pharmaceutical products.

Nov 07, 2018 06:00 am ET

Cipher Pharmaceuticals Reports Q3 2018 Results

Canadian product revenue increased 27%

Oct 24, 2018 05:05 pm ET

Notice of Cipher Pharmaceuticals Q3 2018 Conference Call

MISSISSAUGA, ON, Oct. 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer. The Company will issue its financial results on the morning of November 7, 2018.

Oct 24, 2018 07:00 am ET

Cipher Pharmaceuticals Announces Canadian Launch of Brinavess® (vernakalant hydrochloride)

MISSISSAUGA, ON, Oct. 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of Brinavess® (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation ("AF"), (an irregular and often rapid heart rate that can increase your risk of stroke, heart failure and other heart-related complications) to sinus rhythm ("SR") (a normal heart beat) for non-surgery patients with duration of AF less than seven days and post-cardiac surgery patients with duration of AF less than three days. AF affects approximately 350,000 patients in Canada.1

Sep 18, 2018 07:00 am ET

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis

Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market

Sep 10, 2018 04:00 pm ET

Cipher Pharmaceuticals Receives Health Canada Approval of Xydalba™ (dalbavancin hydrochloride)

MISSISSAUGA, ON, Sept. 10, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it received Health Canada approval of Xydalba™ (dalbavancin hydrochloride), the first and only one-dose treatment option for acute bacterial skin and skin structure infections (ABSSSI) in adults and available in Canada.

Aug 10, 2018 07:00 am ET

Cipher Pharmaceuticals Reports Q2 2018 Results

Canadian product revenue increased 33%

Jul 30, 2018 07:00 am ET

Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica®

Agreement expanded to include a portfolio of novel isotretinoin productsNew portfolio royalty extends through December 2024

Jul 23, 2018 02:00 pm ET

Notice of Cipher Pharmaceuticals Q2 2018 Conference Call

MISSISSAUGA, ON, July 23, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer. Cipher will issue its financial results on the morning of August 10, 2018.

Jun 06, 2018 07:00 am ET

Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs

MISSISSAUGA, ON, June 6, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry medical executive, Dr. Diane Gajewczyk, has joined the Company in the position of Vice President, Scientific and Medical Affairs. Dr. Gajewczyk has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.

May 16, 2018 08:00 am ET

Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

MISSISSAUGA, ON, May 16, 2018 /CNW/ - Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. ("Cardiome") was completed by way of the acquisition by Cipher of all of the issued and outstanding common shares of Cardiome ("Common Shares") following a restructuring of Cardiome pursuant to a court-approved plan of arrangement of Cardiome carried out under Section 192 of the Canada Business Corporations Act (the "Arrangement"). Pursuant to the Arrangement, shareholders of Cardiome prior to

May 15, 2018 09:00 am ET

Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma

MISSISSAUGA, ON, May 15, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced strategic acquisition of the Canadian business portfolio of Cardiome Pharma Corp. (originally disclosed on March 20, 2018). The acquisition was completed pursuant to the terms and conditions of the definitive arrangement agreement, dated March 19, 2018, endered into between Cipher, Cardiome and Correvio Pharma Corp.

May 11, 2018 12:00 pm ET

Cipher Pharmaceuticals Reports Voting Results for the Election of Directors

MISSISSAUGA, ON, May 11, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on May 10, 2018 in Toronto, Ontario.

May 10, 2018 07:00 am ET

Cipher Pharmaceuticals Reports Q1 2018 Results

Company announces four transactions year to date adding revenue diversification and growth avenues in new therapeutic categories

May 01, 2018 07:00 am ET

Notice of Cipher Pharmaceuticals Q1 2018 Conference Call & Annual Meeting

MISSISSAUGA, ON, May 1, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2018 financial results conference call and Annual and Special Meeting of shareholders on Thursday, May 10, 2018.

Apr 26, 2018 07:00 am ET

Cipher Pharmaceuticals Proposes Adding Dr. Laurence Terrisse-Rulleau To Board of Directors

MISSISSAUGA, ON, April 26, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 19, 2018.

Apr 24, 2018 07:00 am ET

Cipher Pharmaceuticals to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, ON, April 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Robert Tessarolo, President and Chief Executive Officer, will present at the 2018 Bloom Burton & Co. Healthcare Investor Conference in Toronto. Mr. Tessarolo will provide a corporate update on Wednesday, May 2, 2018 at 10:00 AM ET followed by a Q&A session.

Apr 23, 2018 07:00 am ET

Cipher Pharmaceuticals Provides Corporate Update and Preliminary Q1 2018 Revenue Results

MISSISSAUGA, ON, April 23, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today provided a strategic and operational update and preliminary revenue results for the three months ended March 31, 2018. The Company will issue its complete Q1 2018 financial results on May 10, 2018.

Apr 06, 2018 07:00 am ET

Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada

The agreement will expand the availability of the first and only U.S. FDA-approved prescription product for the treatment of raised seborrheic keratoses (SKs)

Apr 06, 2018 07:00 am ET

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics

Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratoses (SKs)

Mar 20, 2018 07:00 am ET

Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of $25.5 Million CAD

Mar 20, 2018 07:00 am ET

Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

Feb 28, 2018 06:01 am ET

Cipher Pharmaceuticals Reports Q4 & FY2017 Results

90% increase in revenue and 214% increase in income from continuing operations for Q4 2017Canadian launch of OZANEX™ in Jan 2018Acquired Canadian rights to TRULANCE® in Feb 2018

Feb 28, 2018 06:00 am ET

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals

A new differentiated treatment option for GI disorders

Feb 28, 2018 06:00 am ET

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals

A new differentiated treatment option for GI disorders

Feb 09, 2018 06:00 am ET

Notice of Cipher Pharmaceuticals Q4 and Year-End 2017 Conference Call

MISSISSAUGA, ON, Feb. 9, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 and full-year 2017 financial results conference call on Wednesday, February 28, 2018.

Jan 09, 2018 06:00 am ET

Cipher Pharmaceuticals and Italmex Pharma Announce Exclusive Distribution Agreement for Isotretinoin Product in Mexico

MISSISSAUGA, ON, Jan. 9, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has entered into an exclusive distribution and supply agreement with Italmex Pharma S.A. ("Italmex") under which Cipher has granted Italmex exclusive rights to market, sell and distribute Cipher's Isotretinoin product in Mexico.

Jan 08, 2018 06:30 am ET

Cipher Pharmaceuticals Announces Canadian Launch of OZANEX™ (ozenoxacin cream 1%), a Novel Topical Antibiotic

MISSISSAUGA, ON, Jan. 8, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo in patients aged 2 months and older1.

Nov 03, 2017 08:30 am ET

Cipher Pharmaceuticals Announces New Credit Facility

Substantially reduces cost of capital and interest expense, provides additional capacity to support future growth

Nov 03, 2017 07:00 am ET

Cipher Pharmaceuticals Reports Q3 2017 Operating & Financial Results

Strong Q3 performance 29% revenue growth and 77% growth in income from continuing operations Production resumes at Puerto Rico manufacturing facilities MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2017. Unless otherwise noted, all figures are in U.S. currency.

Oct 17, 2017 10:31 am ET

Notice of Cipher Pharmaceuticals Q2 2017 conference call

MISSISSAUGA, ON, Oct. 17, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q3 2017 financial results conference call on Friday, November 3, 2017.

Oct 10, 2017 08:00 am ET

Cipher Pharmaceuticals Comments on Supply Chain Impact from Hurricane Maria

MISSISSAUGA, ON, Oct. 10, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on the impact from Hurricane Maria to its manufacturing partner's facilities in Puerto Rico. Galephar Pharmaceutical Research ("Galephar") operates two manufacturing facilities in Puerto Rico. The facility in Humacao manufactures Absorica®, Epuris®, and Lipofen® products, and the facility in Juncos manufactures Conzip® and Durela® products.

Sep 07, 2017 08:00 am ET

Cipher Pharmaceuticals Comments on FDA Warning Letter for ConZip® (Tramadol)

MISSISSAUGA, ON, Sept. 7, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on a warning letter issued to Cipher by the Office of Prescription Drug Promotion of the U.S. Food and Drug Administration ("FDA") relating to the professional detail aids for ConZip® (tramadol hydrochloride) extended-release capsules.

Aug 11, 2017 08:00 am ET

Cipher Pharmaceuticals reports Q2 2017 financial results

Company achieves important strategic milestones, delivers strong financial results

Jul 25, 2017 09:00 am ET

Notice of Cipher Pharmaceuticals Q2 2017 Conference Call

MISSISSAUGA, ON, July 25, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2017 financial results conference call on Friday, August 11, 2017.

Jun 02, 2017 08:00 am ET

Cipher Pharmaceuticals Adds New Vice President of Corporate Development

MISSISSAUGA, ON, June 2, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Chris Watters has joined the Company in the new position of Vice President, Corporate Development. Mr. Watters has 19 years of experience in the pharmaceutical industry, including leadership roles in business strategy, marketing, sales and business development.

May 16, 2017 08:00 am ET

Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study

PETACH TIKVA, Israel, May 16, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it has filed a Clinical Trial Application (CTA) with Health Canada for Piclidenoson. Can-Fite has a Canadian distribution partner, Cipher Pharmaceuticals Inc. (Cipher) (TSX: CPH).

May 12, 2017 11:23 am ET

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

MISSISSAUGA, ON, May 12, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual Meeting of Shareholders held on May 11, 2017 in Toronto, Ontario.

May 11, 2017 08:00 am ET

Cipher Pharmaceuticals reports Q1 2017 financial results

Results highlighted by 92% increase in Adjusted EBITDA, 18% increase in revenue

May 08, 2017 08:00 am ET

Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX™ (ozenoxacin cream 1%)

MISSISSAUGA, ON, May 8, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Health Canada approval of OZANEX™ (ozenoxacin cream, 1%) a novel topical antibiotic indicated for the treatment of impetigo in patients aged 2 months and older1.

May 01, 2017 08:00 am ET

Cipher Pharmaceuticals Announces Sale of U.S. Commercial Assets to EPI Group

MISSISSAUGA, ON, May 1, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has completed an agreement (the "Agreement") to sell substantially all of the assets of Cipher Pharmaceuticals US LLC ("Cipher US"), a wholly owned subsidiary of Cipher, to EPI Health, LLC ("EPI"), a wholly owned subsidiary of EPI Group, LLC. The Company had previously disclosed it was pursuing strategic options for its U.S. business.

Apr 27, 2017 12:00 pm ET

Notice of Cipher Pharmaceuticals Q1 2017 Conference Call & Annual Meeting

MISSISSAUGA, ON, April 27, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2017 financial results conference call and Annual Meeting of shareholders on Thursday, May 11, 2017.

Apr 03, 2017 08:30 am ET

Cipher Pharmaceuticals announces amendment to debt agreement and partial prepayment

MISSISSAUGA, ON, April 3, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that it has completed an amendment to the securities purchase agreement (the "Amendment") with investment funds managed by Athyrium Capital Management ("Athyrium"). Unless otherwise noted, all figures are in U.S. currency.

Mar 20, 2017 05:00 pm ET

Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO

MISSISSAUGA, ON, March 20, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief Executive Officer of Cipher, effective April 17, 2017. Mr. Tessarolo will also be nominated for election as a director at the Company's next annual general meeting in May 2017.

Mar 02, 2017 07:00 am ET

Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial Results

MISSISSAUGA, ON, March 2, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2016. Unless otherwise noted, all figures are in U.S. currency.

Feb 16, 2017 04:15 pm ET

Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2016 Conference Call

MISSISSAUGA, ON, Feb. 16, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it will host a conference call its Q4 and full-year 2016 financial results on Thursday, March 2, 2017.

Nov 11, 2016 07:00 am ET

Cipher Pharmaceuticals Reports Q3 2016 Financial Results

MISSISSAUGA, ON, Nov. 11, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2016. Unless otherwise noted, all figures are in U.S. currency.

Nov 11, 2016 07:00 am ET

Cipher Pharmaceuticals Reports Q3 2016 Financial Results

MISSISSAUGA, ON, Nov. 11, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2016. Unless otherwise noted, all figures are in U.S. currency.

Nov 11, 2016 06:30 am ET

Cipher Pharmaceuticals Announces Management Change

MISSISSAUGA, ON, Nov. 11, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, Chief Financial Officer and Secretary of the Company, has been named Interim Chief Executive Officer, replacing Shawn O'Brien, who is pursuing other opportunities. Cipher has commenced a formal search process for a new Chief Executive Officer.

Nov 11, 2016 06:30 am ET

Cipher Pharmaceuticals Announces Management Change

MISSISSAUGA, ON, Nov. 11, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, Chief Financial Officer and Secretary of the Company, has been named Interim Chief Executive Officer, replacing Shawn O'Brien, who is pursuing other opportunities. Cipher has commenced a formal search process for a new Chief Executive Officer.

Oct 27, 2016 10:00 am ET

Notice of Cipher Pharmaceuticals Inc. Q3 2016 Conference Call

MISSISSAUGA, ON, Oct. 27, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q3 2016 financial results on Friday, November 11, 2016.

Oct 27, 2016 10:00 am ET

Notice of Cipher Pharmaceuticals Inc. Q3 2016 Conference Call

MISSISSAUGA, ON, Oct. 27, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q3 2016 financial results on Friday, November 11, 2016.

Sep 01, 2016 06:00 pm ET

Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial Officer

Company also announces appointment of Dr. John Mull as Chair of the Board of Directors

Sep 01, 2016 06:00 pm ET

Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial Officer

Company also announces appointment of Dr. John Mull as Chair of the Board of Directors

Aug 10, 2016 08:00 am ET

Cipher Pharmaceuticals Reports Q2 2016 Results Highlighted by 32% Revenue Growth and $3.1 Million Cash from Operations

MISSISSAUGA, ON, Aug. 10, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2016. Unless otherwise noted, all figures are in U.S. currency. Q2 2015 financial information includes results of U.S. operations starting April 13, 2015, the date of the Innocutis acquisition.

Aug 10, 2016 08:00 am ET

Cipher Pharmaceuticals Reports Q2 2016 Results Highlighted by 32% Revenue Growth and $3.1 Million Cash from Operations

MISSISSAUGA, ON, Aug. 10, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2016. Unless otherwise noted, all figures are in U.S. currency. Q2 2015 financial information includes results of U.S. operations starting April 13, 2015, the date of the Innocutis acquisition.

Aug 09, 2016 08:00 am ET

Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors

MISSISSAUGA, ON, Aug. 9, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board").

Aug 09, 2016 08:00 am ET

Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors

MISSISSAUGA, ON, Aug. 9, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board").

Aug 03, 2016 09:51 am ET

Cipher Pharmaceuticals Announces Preliminary Q2 2016 Results Highlighted by 30+% Revenue Growth and $3.0+million Cash from Operations

MISSISSAUGA, ON, Aug. 3, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced preliminary estimates of its financial results for the three months ended June 30, 2016. The complete financial statements for the Company's second quarter will be released on August 10, 2016, followed by a conference call with management. These preliminary financial results are subject to completion of the Company's customary quarterly closing and review procedures. Unless otherwise noted, all figures are in U.S. currency.

Aug 03, 2016 09:51 am ET

Cipher Pharmaceuticals Announces Preliminary Q2 2016 Results Highlighted by 30+% Revenue Growth and $3.0+million Cash from Operations

MISSISSAUGA, ON, Aug. 3, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced preliminary estimates of its financial results for the three months ended June 30, 2016. The complete financial statements for the Company's second quarter will be released on August 10, 2016, followed by a conference call with management. These preliminary financial results are subject to completion of the Company's customary quarterly closing and review procedures. Unless otherwise noted, all figures are in U.S. currency.

Jul 20, 2016 01:00 pm ET

Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call

MISSISSAUGA, ON, July 20, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016.

Jul 20, 2016 01:00 pm ET

Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call

MISSISSAUGA, ON, July 20, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016.

Jul 12, 2016 08:00 am ET

Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada

MISSISSAUGA, ON, July 12, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Ozenoxacin has been accepted for review by Health Canada. Ozenoxacin is a topical treatment proposed for use in adult and paediatric patients with impetigo, a highly contagious bacterial skin infection. Cipher acquired the Canadian commercialization rights to Ozenoxacin from Ferrer International SA ("Ferrer"), a privately-held Spanish pharmaceutical company, in January 2015.

Jul 12, 2016 08:00 am ET

Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada

MISSISSAUGA, ON, July 12, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Ozenoxacin has been accepted for review by Health Canada. Ozenoxacin is a topical treatment proposed for use in adult and paediatric patients with impetigo, a highly contagious bacterial skin infection. Cipher acquired the Canadian commercialization rights to Ozenoxacin from Ferrer International SA ("Ferrer"), a privately-held Spanish pharmaceutical company, in January 2015.

Jul 06, 2016 11:00 am ET

Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited

MISSISSAUGA, ON, July 6, 2016 /CNW/ - A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report (the "EWR") filed on July 5, 2016 by 1207407 Ontario Limited ("1207407"), a company wholly owned by Dr. John D. Mull. The Special Committee, comprised of directors Stephen Wiseman, Thomas Wellner, William Claypool and Stefan Aigner, was established to address issues of the type referred to in the EWR.

Jul 06, 2016 11:00 am ET

Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited

MISSISSAUGA, ON, July 6, 2016 /PRNewswire/ - A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report (the "EWR") filed on July 5, 2016 by 1207407 Ontario Limited ("1207407"), a company wholly owned by Dr. John D. Mull. The Special Committee, comprised of directors Stephen Wiseman, Thomas Wellner, William Claypool and Stefan Aigner, was established to address issues of the type referred to in the EWR.

Jun 20, 2016 08:00 am ET

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders

MISSISSAUGA, ON, June 20, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders. ASF-1096 is a phase II product candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders. Cipher acquired the global rights to the product in February 2015. Under this agreement, Cipher retains all rights to ASF-1096 for dermatological conditions.

Jun 20, 2016 08:00 am ET

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders

MISSISSAUGA, ON, June 20, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders. ASF-1096 is a phase II product candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders. Cipher acquired the global rights to the product in February 2015. Under this agreement, Cipher retains all rights to ASF-1096 for dermatological conditions.

May 31, 2016 11:00 am ET

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences

MISSISSAUGA, ON, May 31, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences.

May 31, 2016 11:00 am ET

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences

MISSISSAUGA, ON, May 31, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences.

May 06, 2016 09:00 am ET

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

MISSISSAUGA, ON, May 6, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special Meeting of Shareholders held on May 5, 2016 in Toronto, Ontario.

May 06, 2016 09:00 am ET

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

MISSISSAUGA, ON, May 6, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special Meeting of Shareholders held on May 5, 2016 in Toronto, Ontario.

May 05, 2016 08:00 am ET

Cipher Pharmaceuticals Reports Q1 2016 Financial Results

- Revenue increased 23%- Delivered on multiple commercial and regulatory milestones- Positive cash from operating activities of $1.4 million while investing in future growth

May 05, 2016 08:00 am ET

Cipher Pharmaceuticals Reports Q1 2016 Financial Results

- Revenue increased 23%- Delivered on multiple commercial and regulatory milestones- Positive cash from operating activities of $1.4 million while investing in future growth

May 02, 2016 10:31 am ET

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream

Product candidate may have the potential to transform tattoo removal process

May 02, 2016 10:31 am ET

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream

Product candidate may have the potential to transform tattoo removal process

Apr 22, 2016 03:08 pm ET

Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting

MISSISSAUGA, ON, April 22, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2016 financial results conference call and Annual and Special Meeting of shareholders on Thursday, May 5, 2016.

Apr 22, 2016 03:08 pm ET

Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting

MISSISSAUGA, ON, April 22, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2016 financial results conference call and Annual and Special Meeting of shareholders on Thursday, May 5, 2016.

Apr 22, 2016 11:00 am ET

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

MISSISSAUGA, ON, April 22, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his current role to ensure a smooth transition of responsibilities, and the Company has commenced a formal search process for a new CFO.

Apr 22, 2016 11:00 am ET

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

MISSISSAUGA, ON, April 22, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his current role to ensure a smooth transition of responsibilities, and the Company has commenced a formal search process for a new CFO.

Apr 07, 2016 08:00 am ET

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

MISSISSAUGA, ON, April 7, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.

Apr 07, 2016 08:00 am ET

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

MISSISSAUGA, ON, April 7, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.

Apr 06, 2016 05:00 pm ET

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board

MISSISSAUGA, ON, April 6, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and Pruridexin). Both products were approved in Canada by the Natural and Non-Prescription Health Products Directorate. In addition European approval of Helioclin® Pruritus SD Cream (also known as Pruridexin) was achieved.

Apr 06, 2016 05:00 pm ET

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board

MISSISSAUGA, ON, April 6, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and Pruridexin). Both products were approved in Canada by the Natural and Non-Prescription Health Products Directorate. In addition European approval of Helioclin® Pruritus SD Cream (also known as Pruridexin) was achieved.

Apr 05, 2016 05:00 pm ET

Cipher Pharmaceuticals announces Canadian launch of Beteflam™

Represents Fourth Product in Cipher's Growing Canadian Portfolio

Apr 05, 2016 05:00 pm ET

Cipher Pharmaceuticals announces Canadian launch of Beteflam™

Represents Fourth Product in Cipher's Growing Canadian Portfolio

Mar 04, 2016 07:00 am ET

Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business

MISSISSAUGA, ON, March 4, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ralph Bohrer has joined the Company in the position of President and General Manager of its U.S. subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies.

Mar 04, 2016 07:00 am ET

Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business

MISSISSAUGA, ON, March 4, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ralph Bohrer has joined the Company in the position of President and General Manager of its U.S. subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies.

Mar 03, 2016 08:43 am ET

Cipher Pharmaceuticals to Present at Two Upcoming Investor Conferences

MISSISSAUGA, ON, March 3, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences.

Mar 03, 2016 08:43 am ET

Cipher Pharmaceuticals to Present at Two Upcoming Investor Conferences

MISSISSAUGA, ON, March 3, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences.

Feb 24, 2016 07:07 am ET

Cipher Pharmaceuticals Reports 2015 Financial Results

Q4 revenue up 30%, Company significantly advances strategic plans to build adermatology growth company

Feb 24, 2016 07:07 am ET

Cipher Pharmaceuticals Reports 2015 Financial Results

Q4 revenue up 30%, Company significantly advances strategic plans to build adermatology growth company

Feb 22, 2016 07:00 am ET

Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall™

MISSISSAUGA, ON, Feb. 22, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients1. Actinic keratosis, also known as solar keratosis, is a skin condition caused by exposure to ultraviolet radiation2. Cipher acquired Actikerall™ from Almirall S.A. in May, 2015. The

Feb 22, 2016 07:00 am ET

Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall™

MISSISSAUGA, ON, Feb. 22, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients1. Actinic keratosis, also known as solar keratosis, is a skin condition caused by exposure to ultraviolet radiation2. Cipher acquired Actikerall™ from Almirall S.A. in May, 201

Feb 16, 2016 07:00 am ET

Cipher Pharmaceuticals Inc. announces Sitavig™ accepted for review by Health Canada

MISSISSAUGA, ON, Feb. 16, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Sitavig™ has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis (cold sores) in adults.

Feb 16, 2016 07:00 am ET

Cipher Pharmaceuticals Inc. announces Sitavig™ accepted for review by Health Canada

MISSISSAUGA, ON, Feb. 16, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Sitavig™ has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis (cold sores) in adults.

Feb 09, 2016 08:38 am ET

Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2015 Conference Call

MISSISSAUGA, ON, Feb. 9, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it will host a conference call for its Q4 and full-year 2015 financial results on Wednesday, February 24, 2016.

Feb 09, 2016 08:38 am ET

Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2015 Conference Call

MISSISSAUGA, ON, Feb. 9, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it will host a conference call for its Q4 and full-year 2015 financial results on Wednesday, February 24, 2016.

Jan 22, 2016 09:00 am ET

The Life Sciences Report Interviews Alan Leong of BioWatch News

Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. In some cases he will follow a company's clinical development program and data...

Ad blocking detected

Cipher Pharmaceuticals Inc. (T:CPH)

Business Focus: Pharmaceuticals (NEC)